Aptevo Therapeutics Reports $13.1 Million Net Loss and Zero Revenue for First Half of 2026

Aptevo Therapeutics Inc. reported a net loss of $13.1 million for the six months ended June 30, 2026, compared to a net loss of $12.6 million for the same period in 2025. The company’s total revenue remained at zero, as it has not yet commercialized any products. Operating expenses increased to $7.6 million for the first half of 2026, up from $7.0 million in the prior year, primarily due to higher costs associated with the clinical study of its lead candidate, mipletamig, and other preclinical projects. The company’s accumulated deficit reached $288.3 million as of June 30, 2026, reflecting ongoing investment in research and development.

In terms of liquidity, Aptevo's cash and cash equivalents decreased to $9.8 million from $21.6 million at the end of 2025. The company raised approximately $1.6 million through the issuance of common stock during the first half of 2026, significantly lower than the $14.4 million raised in the same period of 2025. The company has entered into Standby Equity Purchase Agreements (SEPAs) with Yorkville, allowing it to raise up to $85 million in total, of which $66.8 million remains available. However, the company has expressed substantial doubt about its ability to continue as a going concern without additional funding.

Strategically, Aptevo has made significant developments, including a collaboration agreement with Niowave, Inc. to develop radiopharmaceutical product candidates, which includes an equity investment of $500,000 from Niowave. Additionally, the company received a $1.5 million grant from the Andy Hill Cancer Research Endowment to support IND-enabling studies for its trispecific antibody candidate, APVO451. These collaborations are expected to enhance Aptevo's research capabilities and product pipeline.

Operationally, Aptevo is advancing its clinical programs, particularly the Phase 1b/2 RAINIER trial for mipletamig, which is being evaluated in combination with standard-of-care treatments for acute myeloid leukemia. The company appointed Mary J. Janatpour, Ph.D., as Senior Vice President and Chief Scientific Officer to lead its research and preclinical development efforts. As of June 30, 2026, Aptevo had 1,418,952 shares of common stock outstanding, reflecting an increase from the previous year, and continues to face challenges in maintaining compliance with Nasdaq listing requirements.

Looking ahead, Aptevo anticipates ongoing operating losses as it continues to invest in the development of its product candidates. The company will need to secure additional funding to support its operations and clinical trials, as its current cash reserves are not expected to sustain operations for the next year. The management has indicated that the ability to raise capital will be critical to the company's future success, particularly in light of the competitive landscape and the need for continued investment in research and development.